Related Experiment Video

Updated: Feb 27, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.6K

Addressing the challenges of phenotyping pediatric pulmonary vascular disease

Kara N Goss1, Allen D Everett2, Peter M Mourani3

  • 1Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Pulmonary Circulation
|July 7, 2017
PubMed

Insights

Pediatric pulmonary vascular disease (PVD) and pulmonary hypertension (PH) are diverse conditions causing significant illness in children. This review emphasizes better recognition, diagnosis, and tailored treatments for pediatric PH to improve long-term outcomes.

Area of Science:

  • Pediatric cardiology and pulmonology.
  • Vascular biology and disease mechanisms.

Background:

  • Pediatric pulmonary vascular disease (PVD) and pulmonary hypertension (PH) are complex conditions.
  • These diseases contribute significantly to morbidity and mortality in children.

Purpose of the Study:

  • To review the multifactorial nature of pediatric PVD.
  • To emphasize improved recognition, phenotyping, and endotyping strategies for pediatric PH.
  • To highlight novel diagnostic and treatment approaches and their impact on long-term outcomes.

Main Methods:

  • Literature review focusing on pediatric PVD and PH.
  • Analysis of current diagnostic and therapeutic strategies.
  • Discussion of phenotyping and endotyping advancements.

Main Results:

  • Pediatric PVD and PH are diverse with complex underlying causes.
  • Improved phenotyping and endotyping are crucial for targeted therapies.
  • Novel approaches offer potential for better management and outcomes.

Conclusions:

  • Accurate diagnosis and tailored treatments are essential for pediatric PVD/PH.
  • Understanding disease heterogeneity is key to improving patient care.
  • Further research into novel strategies will enhance long-term prognosis.

Keywords:
childhoodlong-term outcomespulmonary hypertensionregistry studies

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

11.2K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
710
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57